XW003 bụ akwụkwọ akụkọ, glucagon na-adịte aka dị ka peptide-1 (GLP-1) nke emepụtara na Sciwind Biosciences. E gosiputara na ọ dị mma yana nnabata nke ọma, yana butere mbelata ịdị arọ dabere na dose na nnwale ụlọ ọgwụ n'oge.
Otu n'ime ọtụtụ etiti, randomized, labelụ mepere emepe, na-arụ ọrụ na-achịkwa usoro 2b na-eme atụmatụ ịtụle nchịkwa subcutaneous otu ugboro kwa izu nke XW003 n'ime ihe dịka ndị ọrịa 200 nwere oke ibu. Ndị sonyere na nnwale ahụ, nke a na-eme na Australia na New Zealand, ga-eji ọgwụ ọmụmụ ihe ruo izu 26, na-esote oge nleba anya na-enweghị ọgwụgwọ nke izu 5. Ebumnuche nke ọmụmụ a bụ iji nyochaa nchekwa, nnabata, na ịdị irè ọgwụgwọ XW003 na ndị ọrịa buru ibu. A na-atụ anya data kachasị elu na ọkara nke abụọ nke 2022. Na mgbakwunye, dị ka akụkụ nke mmemme mmepe zuru oke maka XW003, a na-emekwa nnwale dị iche iche na ndị ọrịa China nwere oke ibu.
"Obi dị anyị ụtọ ịnọgide na-enwe ọganihu ngwa ngwa nke XW003 site na mmepe ụlọ ọgwụ. Mmalite nke dosing ndidi n'ime a multi-center, mba ọmụmụ maka ọgwụgwọ nke oke ibu bụ ihe ọzọ dị mkpa dị ịrịba ama maka ụlọ ọrụ na a siri ike na-agba akaebe maka nraranye na ikike nke otu anyị," Dr. Hai Pan, onye nchoputa na CEO nke Sciwind kwuru. "Anyị kpebisiri ike na-aga n'ihu na mmepe nke XW003, yana ndị ọzọ na-achọ ọgwụ ọjọọ na pipeline Sciwind, maka ọgwụgwọ nke ọrịa metabolic, gụnyere oke ibu, ọrịa shuga, na NASH."